<DOC>
	<DOCNO>NCT00230477</DOCNO>
	<brief_summary>This project randomize , open-label trial adefovir dipivoxil ( Hepsera ) lamivudine combination therapy versus adefovir dipivoxil ( Hepsera ) monotherapy . Both adefovir dipivoxil lamivudine nucleoside analogue approve U.S. FDA treatment chronic hepatitis B . The primary hypothesis subject treat combination therapy see viral DNA count decrease amount great subject treat monotherapy . The secondary hypothesis subject treat combination therapy high HBeAg conversion rate compare historical control subject treat lamivudine adefovir dipivoxil monotherapy .</brief_summary>
	<brief_title>Hepsera Versus Hepsera Plus Lamivudine Treatment Chronic Hepatitis B Patients With Normal ALT</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>old 18 year HBsAg+ screen least 6 month prior study entry HBeAg+ HBV DNA great 6 log10 copies/mL Platelet count great 50,000 platelets/mm3 Hemoglobin great 7.5 g/dL ALT le ULN Estimated creatine clearance &gt; 50 mL/min estimate CrockcroftGault equation ( ( 140age ) x ( kg ) / ( serum creatine x 72 ) ( woman x 0.85 ) ) Female male participant must practice effective form contraception ( male female condom spermicide , diaphragm cervical cap spermicide , intrauterine device , hormonal contraception ) Serum alphafetoprotein less 50 ng/mL within 30 day study entry ChildsPugh score le 7 ascites , variceal bleeding , hepatic encephalopathy able give write informed consent comply study protocol history evidence HIV , hepatitis C hepatitis D know suspected hypersensitivity adefovir nucleoside/nucleotide analog . history clinically significant renal dysfunction active medical psychiatric illness , opinion investigator , would interfere subject treatment , assessment , compliance protocol pregnancy breastfeed receipt systemic corticosteroid within 90 day study entry receipt nephrotoxic drug within 8 week prior study screen expect use agent course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Hepatitis B</keyword>
</DOC>